Pharma Commercial Mock
← All views·CI feed·API docs
AASCO
Meeting Library
AACR Annual Meeting 2026 · San Diego, CA
19 shown of 9,181 total abstracts
  1. Abstract 97702026-04-02 · 19:45 CT · Arie Crown Theater
    Real-world effectiveness of Opdivo vs standard of care in metastatic melanoma
    H. Rugo, F. Andre · Massachusetts General Hospital
    Poster Discussion SessionMelanoma📄🖼️
  2. Abstract 104422026-04-01 · 20:00 CT · Arie Crown Theater
    Biomarker subgroup analysis of Keytruda in metastatic melanoma (the KEYNOTE-535 study)
    M.C. Garassino, J. Brahmer · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionMelanoma📄🖼️
  3. Abstract 103882026-04-02 · 21:30 CT · E450
    CheckMate-299: Opdivo (nivolumab) adjuvant in metastatic melanoma
    T. Mok, R. Herbst, C. Robert, et al. · Mayo Clinic
    Poster Discussion SessionMelanoma📄🖼️
  4. Abstract 99782026-04-02 · 21:45 CT · Arie Crown Theater
    Long-term follow-up of Opdivo maintenance for metastatic melanoma: CheckMate-473
    F. Andre, J. Brahmer, C. Robert · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionMelanoma📄🖼️
  5. Abstract 95812026-04-05 · 21:45 CT · S100A
    Long-term follow-up of Keytruda adjuvant for metastatic melanoma: KEYNOTE-283
    A. Spira, S. Peters, C. Robert, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionMelanoma📄🖼️
  6. Abstract 101032026-04-04 · 18:00 CT · Hall B1
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-633
    H. Borghaei, S. Peters, C. Robert, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionMelanoma📄🖼️
  7. Abstract 99312026-04-03 · 19:30 CT · Hall B1
    Keytruda plus chemotherapy in previously untreated metastatic melanoma: updated analysis from KEYNOTE-685
    P. Schmid, C. Robert, L. Paz-Ares, et al. · Peter MacCallum Cancer Centre
    Poster Discussion SessionMelanoma📄🖼️
  8. Abstract 97832026-04-02 · 14:30 CT · S100A
    Long-term follow-up of Opdivo 3L+ for metastatic melanoma: CheckMate-788
    S. Tolaney, M. Reck · UCSF Helen Diller Family Comprehensive Cancer Center
    Poster Discussion SessionMelanoma📄🖼️
  9. Abstract 99262026-04-01 · 21:45 CT · S406
    Quality of life outcomes with Keytruda in patients with metastatic melanoma
    S. Peters, G. Curigliano · Chinese University of Hong Kong
    Poster Discussion SessionMelanoma📄🖼️
  10. Abstract 102362026-04-05 · 19:00 CT · E450
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-294
    S. Peters, H. Borghaei · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionMelanoma📄🖼️
  11. Abstract 99992026-04-03 · 13:15 CT · Arie Crown Theater
    Long-term follow-up of Keytruda 2L for metastatic melanoma: KEYNOTE-241
    H. Rugo, G. Curigliano · Institut Gustave Roussy
    Poster Discussion SessionMelanoma📄🖼️
  12. Abstract 100662026-04-05 · 15:30 CT · E450
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-438 study)
    H. Rugo, S. Tolaney, J. Cortes · Stanford Cancer Institute
    Poster Discussion SessionMelanoma📄🖼️
  13. Abstract 101182026-04-02 · 18:15 CT · S100A
    Quality of life outcomes with Opdivo in patients with metastatic melanoma
    H. Rugo, C. Robert, H. Borghaei · Institut Gustave Roussy
    Poster Discussion SessionMelanoma📄🖼️
  14. Abstract 98602026-04-01 · 16:00 CT · S406
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-256
    F. Andre, L. Paz-Ares, T. Mok · University of Chicago
    Poster Discussion SessionMelanoma📄🖼️
  15. Abstract 97852026-04-03 · 13:15 CT · Arie Crown Theater
    KEYNOTE-156: Keytruda (pembrolizumab) 1L in metastatic melanoma
    C. Saura, S. Modi, F. Andre, et al. · Vall d'Hebron Institute of Oncology
    Poster Discussion SessionMelanoma📄🖼️
  16. Abstract 101362026-04-01 · 19:45 CT · S406
    Long-term follow-up of Opdivo 3L+ for metastatic melanoma: CheckMate-119
    L. Paz-Ares, R. Herbst · Memorial Sloan Kettering Cancer Center
    Poster Discussion SessionMelanoma📄🖼️
  17. Abstract 104972026-04-05 · 18:30 CT · Arie Crown Theater
    Long-term follow-up of Opdivo 3L+ for metastatic melanoma: CheckMate-651
    J. Brahmer, S. Modi, F. Andre · Peter MacCallum Cancer Centre
    Poster Discussion SessionMelanoma📄🖼️
  18. Abstract 98762026-04-03 · 13:00 CT · Arie Crown Theater
    Opdivo plus chemotherapy in previously untreated metastatic melanoma: updated analysis from CheckMate-187
    S. Tolaney, H. Borghaei, M.C. Garassino, et al. · Mayo Clinic
    Poster Discussion SessionMelanoma📄🖼️
  19. Abstract 104102026-04-05 · 14:45 CT · Hall B1
    Biomarker subgroup analysis of Opdivo in metastatic melanoma (the CheckMate-79 study)
    A. Spira, H. Borghaei, C. Robert, et al. · Mayo Clinic
    Poster Discussion SessionMelanoma📄🖼️
© 2026 American Society of Clinical Oncology · Citations follow JCO supplement format:J Clin Oncol 44, 2026 (suppl 17; abstr XXXX). Demo mock.